Skip to main content
. Author manuscript; available in PMC: 2014 Sep 19.
Published in final edited form as: Cochrane Database Syst Rev. 2010 Nov 10;(11):CD006633. doi: 10.1002/14651858.CD006633.pub2
Methods Allocation: randomised.
Blinding: not stated.
Duration:17 weeks.
Participants Diagnosis: (ICD-10) resistant schizophrenia.
N=60.
Age:15 - 60 years.
Gender: 45 M - 15 F.
History:duration of illness clozapine:6.92±5.07 and risperidone:18±4.38 years
Interventions

  1. Clozapine:dose 342.86±84.21 mg/day. N=30.

  2. Risperidone: dose 5.8±1.33 mg/day. N=30.
Outcomes Leaving the study early: any reason, adverse effects, inefficacy.
Clinically important change: at least 20% improvement on PANSS.
Mental state: PANSS total, BPRS modified score, PANSS positive and negative subscore.
Adverse effects: cardiac (tachycardia), extrapyramidal (akatisia), hypersalivation, sedation, weight change
Notes Full text available.